

# Neurocognitive Performance in Post-Acute Sequelae of COVID-19 (PASC)

Kristine Lokken, Ph.D., Melissa J. Greenfield, Psy.D., Jamie Hansel Robinson, M.A., Udit Vipul Shah, B.A., Ronald M. Lazar, Ph.D., Richard Kennedy, Ph.D., Roy C. Martin, Ph.D., Kristen Triebel Gerstenecker, Psy.D., Adam Gerstenecker, Ph.D., Pariya Fazeli Wheeler, Ph.D., Shruti P. Agnihotri, M.D., & David E. Vance, Ph.D.

## Introduction:

- It is now well-documented that SARS-CoV-2 can directly (neuroinvasive) and indirectly (neurovirulent) affect the CNS
- Severe course of COVID-19, delirium during acute illness, pre-existing neurodegenerative disease and psychiatric co-morbidities result in poorer neurocognitive outcomes
- However, patients with even mild course of COVID-19 are reporting persistent cognitive change post-infection
- Few studies have examined neurocognitive performance in patients >12-weeks post infection in an outpatient clinical setting with sensitive neuropsychological measures

## Objective:

- Describe cognitive function in patients seeking treatment for Post-Acute Sequelae of COVID-19 (PASC)


## Methods:

- 92 patients presented for evaluation of “brain fog” following COVID-19 infection
- Patients were referred from the UAB Post-COVID Treatment Program
- Comprehensive neuropsychological assessments were administered

## Results:

**Table 1.** Descriptive Statistics of the Sample

Demographic Category	Description
Age	49.42 (18-74)
Gender	Female (77%)
Race	Caucasian (73%) Black (25%)
Education	15.49



**Table 2:** Average Assessment Scores by Cognitive Domain

Assessment	Standard Score M(SD)	Classification
<b>Global Cognitive Function</b>		
MoCA (Raw Score)	24.78(3.46)	Impaired
<b>Attention &amp; Concentration</b>		
WAIS-IV Digit Span	96.75(12.54)	Average
<b>Processing Speed</b>		
Oral SDMT	72.80(20.37)	Below Average
Oral TMT Part A	88.31(37.76)	Low Average
D-KEFS Color Naming	92.16(18.11)	Average
D-KEFS Word Reading	92.86(17.44)	Average
COWAT FAS	92.03(14.19)	Average
<b>Executive Function</b>		
Oral TMT Part B	92.71(28.48)	Average
D-KEFS Inhibition	90.26(20.66)	Average
D-KEFS Inhibition/Switching	92.95(18.81)	Average
<b>Language</b>		
Animals	95.05(15.78)	Average
<b>Visuospatial Construction</b>		
RBANS Figure Copy	104.04(16.08)	Average
<b>Memory</b>		
CVLT-3 Total Word Recall (Raw Score)	25.28(4.77)	
CVLT-3 Long Delay Free Recall	94.17(19.11)	Average
<b>Effort &amp; Validity</b>		
WAIS-IV Reliable Digit Span (Raw Score)	8.99	95% Valid
CVLT-3 Forced Choice (Raw Score)	8.87	93% Valid

## Conclusion:

- Literature on neuropsychological outcomes of COVID-19 is scarce and poorly described (heterogeneity of patients, methods, time frame, screening measures versus full battery of tests)
- Findings from this study suggest that patients with “brain fog” following COVID-19 infection experience difficulties in specific domains of cognitive functioning
- “Brain fog” secondary to PASC can result in reported persistent health and neuropsychiatric issues that can impact ability to work and QOL
- Further investigation of neuropsychological profiles associated with PASC is warranted to inform diagnosis, neurocognitive trajectory, and treatment planning

## Acknowledgments

This work is supported by the UAB Evelyn F. McKnight Brain Institute

Check out our other posters and supplemental information regarding our UAB NeuroCOVID Database here:

